[go: up one dir, main page]

WO1999011791A3 - Tumor necrosis factor family receptors and ligands, encoding nucleic acids and related binding agents - Google Patents

Tumor necrosis factor family receptors and ligands, encoding nucleic acids and related binding agents Download PDF

Info

Publication number
WO1999011791A3
WO1999011791A3 PCT/US1998/018393 US9818393W WO9911791A3 WO 1999011791 A3 WO1999011791 A3 WO 1999011791A3 US 9818393 W US9818393 W US 9818393W WO 9911791 A3 WO9911791 A3 WO 9911791A3
Authority
WO
WIPO (PCT)
Prior art keywords
ligands
necrosis factor
tumor necrosis
nucleic acids
binding agents
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1998/018393
Other languages
French (fr)
Other versions
WO1999011791A2 (en
Inventor
Preet M Chaudhary
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Washington
Original Assignee
University of Washington
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Washington filed Critical University of Washington
Priority to AU93764/98A priority Critical patent/AU9376498A/en
Publication of WO1999011791A2 publication Critical patent/WO1999011791A2/en
Publication of WO1999011791A3 publication Critical patent/WO1999011791A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The invention provides novel receptors of the tumor necrosis factor receptor family as well as ligands of the tumor necrosis factor family. In addition to the isolated receptors and ligands of the invention, there are provided encoding nucleic acids and related selective binding agents.
PCT/US1998/018393 1997-09-05 1998-09-04 Tumor necrosis factor family receptors and ligands, encoding nucleic acids and related binding agents Ceased WO1999011791A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU93764/98A AU9376498A (en) 1997-09-05 1998-09-04 Tumor necrosis factor family receptors and ligands, encoding nucleic acids and related binding agents

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US92463497A 1997-09-05 1997-09-05
US08/924,634 1997-09-05

Publications (2)

Publication Number Publication Date
WO1999011791A2 WO1999011791A2 (en) 1999-03-11
WO1999011791A3 true WO1999011791A3 (en) 1999-09-30

Family

ID=25450466

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1998/018393 Ceased WO1999011791A2 (en) 1997-09-05 1998-09-04 Tumor necrosis factor family receptors and ligands, encoding nucleic acids and related binding agents

Country Status (2)

Country Link
AU (1) AU9376498A (en)
WO (1) WO1999011791A2 (en)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6902910B2 (en) 1997-01-28 2005-06-07 Human Genome Sciences, Inc. Death domain containing receptor 4
US7314619B2 (en) 1997-05-15 2008-01-01 Genentech, Inc. Inducing apoptosis using anti-Apo-2 antibodies
US7348003B2 (en) 2001-05-25 2008-03-25 Human Genome Sciences, Inc. Methods of treating cancer using antibodies that immunospecifically bind to TRAIL receptors
US7361341B2 (en) 2001-05-25 2008-04-22 Human Genome Sciences, Inc. Methods of treating cancer using antibodies that immunospecifically bind to trail receptors
US7402658B2 (en) 1997-09-12 2008-07-22 Biogen Idec Ma Inc. TRAIN-R: a cysteine-rich member of the TNF-receptor family
US7521048B2 (en) 2005-08-31 2009-04-21 Amgen Inc. TRAIL receptor-2 polypeptides and antibodies
US9017671B2 (en) 2004-10-20 2015-04-28 Genentech, Inc. Method of treating cancer with a pharmaceutical formulation comprising a HER2 antibody

Families Citing this family (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6541224B2 (en) 1996-03-14 2003-04-01 Human Genome Sciences, Inc. Tumor necrosis factor delta polypeptides
US7217788B2 (en) 1996-03-14 2007-05-15 Human Genome Sciences, Inc. Human tumor necrosis factor delta polypeptides
US6812327B1 (en) 1996-10-25 2004-11-02 Human Genome Sciences, Inc. Neutrokine-alpha polypeptides
US6689579B1 (en) 1996-10-25 2004-02-10 Human Genome Sciences, Inc. Polynucleotides encoding neutrokine-α
DE69837996T2 (en) 1997-01-14 2008-02-28 Human Genome Sciences, Inc. TUMOR NECROSE FACTOR RECEPTORS 6 ALPHA & 6 BETA
US7285267B2 (en) 1997-01-14 2007-10-23 Human Genome Sciences, Inc. Tumor necrosis factor receptors 6α & 6β
EP0857782A3 (en) * 1997-01-27 1999-12-22 Smithkline Beecham Corporation Novel mammalian DD-1 gene
US8329179B2 (en) 1997-01-28 2012-12-11 Human Genome Sciences, Inc. Death domain containing receptor 4 antibodies and methods
EP1012274B2 (en) 1997-01-28 2011-06-15 Human Genome Sciences, Inc. Death domain containing receptor 4 (dr4: death receptor 4), member of the tnf-receptor superfamily and binding to trail (ap0-2l)
US7452538B2 (en) 1997-01-28 2008-11-18 Human Genome Sciences, Inc. Death domain containing receptor 4 antibodies and methods
US7528239B1 (en) 1997-02-13 2009-05-05 Immunex Corporation Receptor that binds trail
US6313269B1 (en) * 1997-03-14 2001-11-06 Smithkline Beecham Corporation Tumor necrosis factor related receptor, TR6
IL134578A0 (en) 1997-09-18 2001-04-30 Genentech Inc DcR3 POLYPEPTIDE, A TNFR HOMOLOG
AU1700999A (en) * 1997-11-26 1999-06-15 Eli Lilly And Company Tnf ligand family gene
JP2002503444A (en) * 1997-11-26 2002-02-05 イーライ・リリー・アンド・カンパニー Ligand family genes
CA2316545A1 (en) * 1997-12-29 1999-07-08 Regeneron Pharmaceuticals, Inc. Novel nucleic acid and polypeptide with homology to the tnf-receptors
US6297367B1 (en) 1997-12-30 2001-10-02 Chiron Corporation Polynucleotide encoding TNFL1
WO1999033980A2 (en) * 1997-12-30 1999-07-08 Chiron Corporation Members of tnf and tnfr families
CA2318743A1 (en) * 1998-01-27 1999-07-29 Millennium Pharmaceuticals, Inc. Novel molecules of the tnf receptor superfamily and uses therefor
DE19809978A1 (en) * 1998-03-09 1999-09-16 Basf Ag New soluble member of tumor necrosis factor receptor family, useful for identification specific modulators and for treating disease e.g. tumors
US7488590B2 (en) 1998-10-23 2009-02-10 Amgen Inc. Modified peptides as therapeutic agents
WO2000026244A2 (en) * 1998-11-04 2000-05-11 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services A novel tumor necrosis factor family member, drl, and related compositions and methods
WO2002094852A2 (en) 2001-05-24 2002-11-28 Zymogenetics, Inc. Taci-immunoglobulin fusion proteins
US7833529B1 (en) 1999-01-07 2010-11-16 Zymogenetics, Inc. Methods for inhibiting B lymphocyte proliferation with soluble ztnf4 receptor
TR200102021T2 (en) 1999-01-15 2001-12-21 Biogen, Inc. TWEAK and TWEAK receptor antagonists and their use for the treatment of immunological disorders
CA2360062A1 (en) 1999-01-25 2000-07-27 Biogen, Inc. Baff, inhibitors thereof and their use in the modulation of b-cell response
US20030095967A1 (en) 1999-01-25 2003-05-22 Mackay Fabienne BAFF, inhibitors thereof and their use in the modulation of B-cell response and treatment of autoimmune disorders
US6475986B1 (en) 1999-02-02 2002-11-05 Research Development Foundation Uses of THANK, a TNF homologue that activates apoptosis
AU2574200A (en) * 1999-02-19 2000-09-04 Toshio Kitamura Novel tnf receptor-like proteins
US20030022233A1 (en) 1999-04-30 2003-01-30 Raymond G. Goodwin Methods of use of the taci/taci-l interaction
WO2001004139A2 (en) * 1999-07-13 2001-01-18 Smithkline Beecham Corporation Human axor29 receptor
WO2001011050A1 (en) 1999-08-04 2001-02-15 Amgen Inc. Fhm, A NOVEL MEMBER OF THE TNF LIGAND SUPERGENE FAMILY
WO2001010908A1 (en) 1999-08-04 2001-02-15 Amgen Inc. Ntr3, a member of the tnf-receptor supergene family
SK288603B6 (en) 1999-08-17 2018-10-01 Biogen Ma Inc. Polypeptide and antibody binding to polypeptide
UA74798C2 (en) 1999-10-06 2006-02-15 Байоджен Айдек Ма Інк. Method for treating cancer in mammals using polypeptide interfering with interaction between april and its receptors
CA2391820A1 (en) * 1999-10-22 2001-05-03 Zymogenetics, Inc. Umlr polypeptides
GB9927681D0 (en) * 1999-11-23 2000-01-19 Glaxo Group Ltd Protein
WO2001058953A2 (en) * 2000-02-11 2001-08-16 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services Identification of a domain in the tumor necrosis factor receptor family that mediates pre-ligand receptor assembly and function
WO2001058954A2 (en) * 2000-02-11 2001-08-16 Genetics Institute, Llc. Trade molecules and uses related thereto
AU2048501A (en) 2000-02-16 2001-08-27 Genentech Inc. Uses of agonists and antagonists to modulate activity of tnf-related molecules
PL357939A1 (en) 2000-04-11 2004-08-09 Genentech, Inc. Multivalent antibodies and uses therefor
US7476383B2 (en) 2000-05-02 2009-01-13 The Uab Research Foundation Antibody selective for DR4 and uses thereof
US7279160B2 (en) 2000-05-02 2007-10-09 The Uab Research Foundation Combinations of DR5 antibodies and other therapeutic agents
TWI318983B (en) 2000-05-02 2010-01-01 Uab Research Foundation An antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof
WO2001085193A2 (en) 2000-05-08 2001-11-15 Biogen, Inc. Method for promoting neovascularization using a tweak agonist and an angiogenic factor
AU2001263114A1 (en) 2000-05-12 2001-11-26 Amgen Inc Methods and compositions of matter concerning april/g70, bcma, blys/agp-3, and taci
US7220840B2 (en) 2000-06-16 2007-05-22 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to B lymphocyte stimulator protein
EP2281843B1 (en) 2000-06-16 2016-10-12 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to BLyS
WO2002009755A2 (en) 2000-07-27 2002-02-07 Genentech, Inc. Apo-2l receptor agonist and cpt-11 synergism
US7208151B2 (en) 2001-09-12 2007-04-24 Biogen Idec Ma Inc. Tweak receptor agonists as anti-angiogenic agents
UA83458C2 (en) 2000-09-18 2008-07-25 Байоджен Айдек Ма Інк. The isolated polypeptide baff-r (the receptor of the factor of activation of b-cells of the family tnf)
PL393317A1 (en) 2001-05-11 2011-05-23 Amgen Inc. Peptides and related binding molecules TALL-1
AU2002311976A1 (en) 2001-05-24 2002-12-03 Human Genome Sciences, Inc. Antibodies against tumor necrosis factor delta (april)
JP4309758B2 (en) 2001-05-25 2009-08-05 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド Antibodies that immunospecifically bind to TRAIL receptors
CA2451680C (en) 2001-07-03 2011-04-19 Genentech, Inc. Human dr4 antibodies and uses thereof
AU2002328173A1 (en) * 2001-08-07 2003-02-24 Genset S.A. Omoxin agonists and antagonists for use in the treatment of metabolic disorders
JP2005508162A (en) 2001-10-02 2005-03-31 ジェネンテック・インコーポレーテッド Apo-2 ligand variants and methods of use
US7741285B2 (en) 2001-11-13 2010-06-22 Genentech, Inc. APO-2 ligand/trail formulations
US7842668B1 (en) 2001-11-13 2010-11-30 Genentech, Inc. Apo-2 ligand/trail formulations
IL161812A0 (en) 2001-11-13 2005-11-20 Genentech Inc Apo2 ligand/trail formulations
CN102793921A (en) 2002-04-09 2012-11-28 比奥根艾迪克Ma公司 Methods for treating tweak-related conditions
CA2489348A1 (en) 2002-06-24 2003-12-31 Genentech, Inc. Apo-2 ligand/trail variants and uses thereof
EP1558640B1 (en) * 2002-10-29 2011-04-13 Anaphore, Inc. Trimeric binding proteins for trimeric cytokines
CA2520097C (en) 2003-03-28 2014-10-07 Biogen Idec Ma Inc. Truncated baff receptors
AU2004315198A1 (en) * 2004-01-29 2005-08-18 Genentech, Inc. Variants of the extracellular domain of BCMA and uses thereof
CN101014245A (en) 2004-08-03 2007-08-08 比奥根艾迪克Ma公司 Taj in neuronal function
KR101235479B1 (en) 2004-08-06 2013-02-20 제넨테크, 인크. Analysis and Methods Using Biomarkers
EP1778871B1 (en) 2004-08-06 2011-05-04 Genentech, Inc. Assays and methods using biomarkers
NZ583905A (en) 2004-10-13 2011-12-22 Univ Washington Use of BAFF to Treat Sepsis
EP1836224A1 (en) 2004-12-23 2007-09-26 Laboratoires Serono S.A. Bcma polypeptides and uses thereof
KR101292961B1 (en) 2005-02-02 2013-08-02 더 유에이비 리서치 파운데이션 Agents and methods related to reducing resistance to apoptosis-inducing death receptor agonists
US8029783B2 (en) 2005-02-02 2011-10-04 Genentech, Inc. DR5 antibodies and articles of manufacture containing same
DK2332408T3 (en) 2005-02-17 2013-12-02 Biogen Idec Inc Treatment of neurological diseases
JP5339901B2 (en) 2005-05-10 2013-11-13 バイオジェン・アイデック・エムエイ・インコーポレイテッド Treatment and evaluation of inflammatory injury
WO2006138219A2 (en) 2005-06-13 2006-12-28 Biogen Idec Ma Inc. Methods of diagnosis / prognosis of inflammatory conditions
CA2618763A1 (en) 2005-08-09 2007-02-15 Zymogenetics, Inc. Methods for the treatment and prevention of abnormal cell proliferation using taci-fusion molecules
KR20080056714A (en) 2005-08-09 2008-06-23 지모제넥틱스, 인코포레이티드 How to Treat VIII-Cell Malignancies Using TACI-IGg Fusion Molecules
WO2007022157A2 (en) 2005-08-16 2007-02-22 Genentech, Inc. Apoptosis sensitivity to ap02l/trail by testing for 'galnac-t14 expression in cells/tissues
WO2007062090A2 (en) 2005-11-23 2007-05-31 Genentech, Inc. Methods and compositions related to b cell assays
WO2007092777A2 (en) * 2006-02-02 2007-08-16 Wyeth Cloning, characterization, and application of tnfrsf19 in neurological disorders
JP2009537563A (en) 2006-05-15 2009-10-29 アレス トレーディング ソシエテ アノニム Methods for treating autoimmune diseases using TACI fusion molecules
AU2009303304A1 (en) 2008-10-10 2010-04-15 Anaphore, Inc. Polypeptides that bind TRAIL-RI and TRAIL-R2
JP6292748B2 (en) 2009-11-05 2018-03-14 ザ ユーエービー リサーチ ファンデーション Treatment of basal cell-like genotype cancer
IN2012DN05169A (en) 2009-12-02 2015-10-23 Acceleron Pharma Inc
WO2011109280A1 (en) 2010-03-05 2011-09-09 Lerner Research Institute Methods and compositions to treat immune-mediated disorders
US8703712B2 (en) 2010-03-18 2014-04-22 The Uab Research Foundation Targeting cancer stem cells with DR5 agonists
PH12013500845A1 (en) 2010-10-29 2013-06-24 Daiichi Sankyo Co Ltd Novel anti-dr5 antibody
US20140105898A1 (en) 2011-02-28 2014-04-17 Istituto Di Ricovero E Cura A Carattere Scientific Materno-Infantile Burlo Garo Apoptosis-inducing molecules and uses therefor
MX2013012716A (en) 2011-05-03 2014-03-21 Genentech Inc Vascular disruption agents and uses thereof.
WO2012170938A1 (en) 2011-06-08 2012-12-13 Acceleron Pharma Inc. Compositions and methods for increasing serum half-life
PH12022550138A1 (en) 2013-03-13 2023-03-06 Amgen Inc Proteins specific for baff and b7rp1 and uses thereof
US9458246B2 (en) 2013-03-13 2016-10-04 Amgen Inc. Proteins specific for BAFF and B7RP1
WO2014159562A1 (en) 2013-03-14 2014-10-02 Bristol-Myers Squibb Company Combination of dr5 agonist and anti-pd-1 antagonist and methods of use
EP3323428A1 (en) 2016-11-17 2018-05-23 CNRS Centre National de la Recherche Scientifique Selective c-flip inhibitors as anticancer agents
EP3910331A1 (en) 2020-05-15 2021-11-17 iOmx Therapeutics AG Intracellular kinase associated with resistance against t-cell mediated cytotoxicity, and uses thereof
EP4257132A1 (en) 2022-04-08 2023-10-11 iOmx Therapeutics AG Sik3 inhibitors for treating diseases resistant to death receptor signalling
WO2024175554A1 (en) 2023-02-21 2024-08-29 Institut Curie Trail agonists for use in the treatment of cancer in patients having an activating alteration of fgfr3
EP4642902A1 (en) * 2023-04-21 2025-11-05 National Research Council of Canada Improvement in viral extraction from cell culture

Citations (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997033902A1 (en) * 1996-03-14 1997-09-18 Human Genome Sciences, Inc. Human tumor necrosis factor delta and epsilon
WO1998005783A1 (en) * 1996-08-07 1998-02-12 Biogen, Inc. A tumor necrosis factor related ligand
WO1998018921A1 (en) * 1996-10-25 1998-05-07 Human Genome Sciences, Inc. NEUTROKINE $g(a)
WO1998027114A2 (en) * 1996-12-17 1998-06-25 Schering Corporation Mammalian cell surface antigens; related reagents
WO1998030694A2 (en) * 1997-01-14 1998-07-16 Human Genome Sciences, Inc. TUMOR NECROSIS FACTOR RECEPTORS 6α AND 6$g(b)
WO1998030693A2 (en) * 1997-01-14 1998-07-16 Human Genome Sciences, Inc. Tumor necrosis factor receptor 5
EP0861850A1 (en) * 1997-02-04 1998-09-02 Smithkline Beecham Corporation Tumor necrosis related receptor, TR4
WO1998038304A1 (en) * 1997-02-27 1998-09-03 Ono Pharmaceutical Co., Ltd. Novel polypeptide, dna encoding the same and use thereof
WO1998041629A2 (en) * 1997-03-17 1998-09-24 Human Genome Sciences, Inc. Death domain containing receptor 5
WO1998046643A1 (en) * 1997-04-16 1998-10-22 Millennium Biotherapeutics, Inc. TUMOR NECROSIS FACTOR RECEPTOR RELATED PROTEINS TANGO-63d AND TANGO-63e
WO1998051793A1 (en) * 1997-05-15 1998-11-19 Genentech, Inc. Apo-2 RECEPTOR
WO1998055621A1 (en) * 1997-06-06 1998-12-10 Regeneron Pharmaceuticals, Inc. Ntn-2 member of tnf ligand family
WO1998055620A1 (en) * 1997-06-06 1998-12-10 Regeneron Pharmaceuticals, Inc. Ntn-2 member of tnf ligand family
WO1998058062A1 (en) * 1997-06-18 1998-12-23 Genentech, Inc. Apo-2DcR
WO1999014330A1 (en) * 1997-09-18 1999-03-25 Genentech, Inc. DcR3 POLYPEPTIDE, A TNFR HOMOLOG
EP0911633A1 (en) * 1997-10-08 1999-04-28 Smithkline Beecham Corporation A method of identifying agonists and antagonists for tumor necrosis related receptors TR1, TR3 and TR5

Patent Citations (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997033902A1 (en) * 1996-03-14 1997-09-18 Human Genome Sciences, Inc. Human tumor necrosis factor delta and epsilon
WO1998005783A1 (en) * 1996-08-07 1998-02-12 Biogen, Inc. A tumor necrosis factor related ligand
WO1998018921A1 (en) * 1996-10-25 1998-05-07 Human Genome Sciences, Inc. NEUTROKINE $g(a)
WO1998027114A2 (en) * 1996-12-17 1998-06-25 Schering Corporation Mammalian cell surface antigens; related reagents
WO1998030694A2 (en) * 1997-01-14 1998-07-16 Human Genome Sciences, Inc. TUMOR NECROSIS FACTOR RECEPTORS 6α AND 6$g(b)
WO1998030693A2 (en) * 1997-01-14 1998-07-16 Human Genome Sciences, Inc. Tumor necrosis factor receptor 5
EP0861850A1 (en) * 1997-02-04 1998-09-02 Smithkline Beecham Corporation Tumor necrosis related receptor, TR4
WO1998038304A1 (en) * 1997-02-27 1998-09-03 Ono Pharmaceutical Co., Ltd. Novel polypeptide, dna encoding the same and use thereof
WO1998041629A2 (en) * 1997-03-17 1998-09-24 Human Genome Sciences, Inc. Death domain containing receptor 5
WO1998046643A1 (en) * 1997-04-16 1998-10-22 Millennium Biotherapeutics, Inc. TUMOR NECROSIS FACTOR RECEPTOR RELATED PROTEINS TANGO-63d AND TANGO-63e
WO1998051793A1 (en) * 1997-05-15 1998-11-19 Genentech, Inc. Apo-2 RECEPTOR
WO1998055621A1 (en) * 1997-06-06 1998-12-10 Regeneron Pharmaceuticals, Inc. Ntn-2 member of tnf ligand family
WO1998055620A1 (en) * 1997-06-06 1998-12-10 Regeneron Pharmaceuticals, Inc. Ntn-2 member of tnf ligand family
WO1998058062A1 (en) * 1997-06-18 1998-12-23 Genentech, Inc. Apo-2DcR
WO1999014330A1 (en) * 1997-09-18 1999-03-25 Genentech, Inc. DcR3 POLYPEPTIDE, A TNFR HOMOLOG
EP0911633A1 (en) * 1997-10-08 1999-04-28 Smithkline Beecham Corporation A method of identifying agonists and antagonists for tumor necrosis related receptors TR1, TR3 and TR5

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
CHICHEPORTICHE Y. ET AL.: "TWEAK, a new secreted ligand in the tumor necrosis factor family that weakly induces apoptosis", J. BIOL. CHEM., vol. 272, no. 51, 19 December 1997 (1997-12-19), pages 32401 - 32410, XP002108889 *
CHINNAIYAN A M ET AL: "SIGNAL TRANSDUCTION BY DR3, A DEATH DOMAIN-CONTAINING RECEPTOR RELATED TO TNFR-1 AND CD95", SCIENCE, vol. 274, no. 5289, 8 November 1996 (1996-11-08), pages 990 - 992, XP000676685 *
DATABASE GENBANK 19 July 1996 (1996-07-19), MARRA M. ET AL.: "Mouse embryo EST clone IMAGE:427152", XP002093795 *
DATABASE GENBANK 26 August 1996 (1996-08-26), MARRA M. ET AL.: "Mouse embryo EST clone IMAGE:472300", XP002093796 *
MACFARLANE M ET AL: "IDENTIFICATION AND MOLECULAR CLONING OF TWO NOVEL RECEPTORS FOR THE CYTOTOXIC LIGAND TRAIL", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 272, no. 41, 10 October 1997 (1997-10-10), pages 25417 - 25420, XP002065148 *
PAN G ET AL: "AN ANTAGONIST DECOY RECEPTOR AND A DEATH DOMAIN-CONTAINING RECEPTOR FOR TRAIL", SCIENCE, vol. 277, 8 August 1997 (1997-08-08), pages 815 - 818, XP002065147 *
ROKHLIN O.W. ET AL.: "Fas-mediated apoptosis in human prostatic carcinoma cell lines", CANCER RESEARCH, vol. 57, no. 9, 1 May 1997 (1997-05-01), pages 1758 - 1768, XP002093791 *
SHERIDAN J P ET AL: "Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors", SCIENCE, no. 277, 8 August 1997 (1997-08-08), pages 818 818, XP002075799 *
USLU R. ET AL.: "Chemosensitization of human prostate carcinoma cell lines to anti-fas-mediated cytotoxicity and apoptosis", CLIN. CANCER RESEARCH, vol. 3, no. 6, June 1997 (1997-06-01), pages 963 - 972, XP002093792 *

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6902910B2 (en) 1997-01-28 2005-06-07 Human Genome Sciences, Inc. Death domain containing receptor 4
US7314619B2 (en) 1997-05-15 2008-01-01 Genentech, Inc. Inducing apoptosis using anti-Apo-2 antibodies
US7595046B2 (en) 1997-05-15 2009-09-29 Genentech, Inc. Treatment of cancer using anti-Apo-2 antibodies
US7402658B2 (en) 1997-09-12 2008-07-22 Biogen Idec Ma Inc. TRAIN-R: a cysteine-rich member of the TNF-receptor family
US7838639B2 (en) 1997-09-12 2010-11-23 Biogen Idec Ma Inc. Antibodies to train R: a cysteine-rich member of the TNF-receptor family, and methods of treating tumors expressing said receptor
US7348003B2 (en) 2001-05-25 2008-03-25 Human Genome Sciences, Inc. Methods of treating cancer using antibodies that immunospecifically bind to TRAIL receptors
US7361341B2 (en) 2001-05-25 2008-04-22 Human Genome Sciences, Inc. Methods of treating cancer using antibodies that immunospecifically bind to trail receptors
US9017671B2 (en) 2004-10-20 2015-04-28 Genentech, Inc. Method of treating cancer with a pharmaceutical formulation comprising a HER2 antibody
US7521048B2 (en) 2005-08-31 2009-04-21 Amgen Inc. TRAIL receptor-2 polypeptides and antibodies

Also Published As

Publication number Publication date
AU9376498A (en) 1999-03-22
WO1999011791A2 (en) 1999-03-11

Similar Documents

Publication Publication Date Title
WO1999011791A3 (en) Tumor necrosis factor family receptors and ligands, encoding nucleic acids and related binding agents
WO2000001815A3 (en) Neurotrophic factors
WO2002024909A3 (en) Receptor nucleic acids and polypeptides
WO1999003822A8 (en) Bicyclic metabotropic glutamate receptor ligands
WO2000040614A3 (en) Characterization of the soc/crac calcium channel protein family
CA2200423A1 (en) Novel estrogen receptor
WO2004020405A3 (en) Modified transferrin fusion proteins
ZA983497B (en) Activated protein c formulations.
WO1999015653A3 (en) Tie ligand homologues
IL193886A (en) Antibodies that bind to ldcam sequences
DE69805237D1 (en) Tumor necrosis associated receptor, TR4
WO2001096565A3 (en) Binding agents: chimeric ligand/receptor proteins
NL1010890C2 (en) Stabilizer mixture.
GB9807256D0 (en) Functional protein compositions,emulsions based thereon and processes for their preparation
WO1997011968A3 (en) A gene associated with liver neoplastic disease
WO1998057983A3 (en) Mammalian neuro-growth factor like protein
DE69841176D1 (en) Rtd receptor
AU3208699A (en) P40 protein acts as an oncogene
AU2190801A (en) Binding protein
AU3003095A (en) Proteins associated with tumor necrosis factor receptor
WO2001012664A3 (en) Notch receptor ligands and uses thereof
ZA992214B (en) Oligomeric stabilizer mixture.
AU9130598A (en) Tumor necrosis factor receptor ztnfr-6
WO2000024771A3 (en) Nucleic acids encoding osteoprotegerin-like proteins and methods of using same
WO1998017827A3 (en) Compositions and methods using eukaryotic rad52

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU CA JP

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AU CA JP

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA